

Request under Freedom of Information Act 2000

Thank you for your request for information which we received on Thursday 2nd May 2024. I am pleased to confirm the following.

Could you please list all oncology therapies you currently use (i.e in the last 12 months, or any timeline this would be available for), and the indications in which they are used for?

Oncology Therapies used at MKUH during March 2021-March 2024	
<u>Agent</u>	<u>Indication</u>
Abemaciclib	Breast cancer
Afatinib	Lung cancer
Anastrozole	Breast cancer
Bevacizumab	Cancer of the ovary, hepatocellular carcinoma, Cancer of the cervix
Atezolizumab	Hepatocellular carcinoma, Lung cancer
Cabizantinib	Renal cancer
Cabazitaxel	Prostate cancer
Capecitabine	Colorectal cancer, breast cancer, pancreatic cancer, oesophageal cancer
Carboplatin	Breast cancer, cancer of the ovary, cancer of the cervix, lung cancer, endometrial cancer, neuroendocrine tumors
Ceritinib	Lung cancer
Cetuximab	Colorectal cancer
Cisplatin	Lung cancer, Germ cell tumors, Cholangiocarcinoma, oesophageal , cancer of the bladder
Cyclophosphamide	Breast cancer, lung cancer
Docetaxel	Breast cancer, cancer of the prostate, lung cancer
Dostarlimab	Endometrial cancer
Doxorubicin	Lung cancer
Durvalumab	Lung cancer , Cholangiocarcinoma
Erlotinib	Lung cancer
Encorafenib	Colorectal cancer
Epirubicin	Breast cancer
Eribulin	Breast cancer

Etoposide	Lung cancer, Germ cell tumors, cancer of the ovary
Everolimus	Breast cancer , caner of the pancreas
Exemestane	Breast cancer
Fluorouracil	Colorectal cancer
Fulvestrant	Breast cancer
Gemcitabine	Lung cancer, cancer of the ovary, breast cancer , cancer of the pancreas , cancer of the bladder
Ipilimumab	Lung cancer
Irinotecan	Colorectal cancer, cancer of the pancreas
Lenvatinib	Endometrial cancer
letrozole	Breast cancer
Liposomal doxorubicin	Cancer of the ovary , endometrial cancer
Lomustine	Glioma
Loratinib	Lung cancer
Mitomycin-C bladder instillation	Cancer of the bladder
Neratinib	Breast cancer
Nintedanib	Lung cancer
Niraparib	Ovarian/ uterine cancer
Nivolumab	Lung cancer, oesopahgeal cancer
Olaparib	Ovarian cancer , breast cancer
Osimertinib	Lung cancer
Oxaliplatin	Colorectal cancer
Paclitaxel	Breast cancer, cancer of the anal canal, ovarian cancer, gastric cancer
Paclitaxel Albumin	Breast cancer , cancer of the pancreas
Palbociclib	Breast cancer
Panitumumab	Colorectal cancer
Pembrolizumab	Oesophageal cancer, lung cancer, endometrial cancer, breast cancer
Pemetrexed (Alimta)	Lung cancer
Procarbazine	Astrocytoma, glioma
Pertuzumab	Breast cancer
Raltitrexed	Colorectal cancer
Ribociclib	Breast cancer
Rucaparib	Ovarian cancer
Sacituzumab Govitecan	breast cancer
Tamoxifen	breast cancer
Temozolomide	Glioma

Topotecan	lung cancer
Trastuzumab	Breast cancer, oesophageal cancer, gastric cancer
Trastuzumab Deruxtecan	Breast cancer
Trastuzumab Emtansine (Kadcyla)	Breast cancer
Trifluridine-tipiracil	Colorectal cancer
Tucatinib	Breast cancer
Vincristine	Glioma, Lung cancer
Vinorelbine	Breast cancer

Please be advised that this information is provided in accordance with the Freedom of Information Act 2000 and is for your personal use. Any re-use of this information will be subject to copyright and the Re-Use of Public Sector Information Regulations (1st July 05) and authorisation from Milton Keynes Hospital NHS Foundation Trust will be required. In the event of any re-use, the information must be reproduced accurately and not used in a misleading manner.

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD. If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely

Freedom of Information Co-ordinator
For and on behalf of Milton Keynes Hospital NHS Foundation Trust

Any re-use of this information will be subject to the 'Re-use of Public Sector Information Regulations' and best practice.